J9198 HCPCS Level II code: Injection, gemcitabine hydrochloride, (infugem), 100 mg

J9198 is the HCPCS code for “Injection, gemcitabine hydrochloride, (infugem), 100 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.

Official description

J9198

Injection, gemcitabine hydrochloride, (infugem), 100 mg

Short description: Inj. infugem, 100 mg

HCPCS · United States

Medicare details

The indicators CMS publishes with J9198 in its October 2026 file. They describe Medicare’s handling, not another payer’s.

Medicare coverage
Carrier judgment
Medicare pricing
Drugs
ASC
Approved for ambulatory surgical centers
Type of service
Medical care; Lump sum purchase of DME, prosthetics, orthotics
BETOS category
Chemotherapy
Added
Jul 1, 2020

Where J9198 sits

  1. 1J codesDrugs administered other than orally
  2. 2Active code J9198Injection, gemcitabine hydrochloride, (infugem), 100 mg

Source and release

Data release
HCPCS Level II · October 2026
Effective date
Oct 1, 2026
Publisher
CMS

This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.

Frequently asked questions

What does HCPCS code J9198 mean?

J9198 is the HCPCS code for “Injection, gemcitabine hydrochloride, (infugem), 100 mg” in CMS’s HCPCS Level II October 2026 release.

Does Medicare cover J9198?

CMS lists J9198’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.

Which HCPCS Level II release does this page use?

It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.